Advertisement
BRKR vs WAT
Which Stock Would AI Choose? Bruker (BRKR) vs. Waters (WAT) Stock Comparison
Key Takeaways
- BRKR has delivered substantially stronger year-to-date and one-year returns compared with WAT, reflecting more robust recent momentum in the analytical instruments sector.
- Both companies operate in life-sciences tools and analytical instrumentation, with overlapping exposure to pharmaceutical, academic, and industrial end markets.
- WAT maintains a larger market capitalization and typically trades at a premium valuation, supported by consistent cash-flow generation and established product lines.
- Upcoming second-quarter 2026 earnings releases scheduled for the same date provide a near-term catalyst window for both stocks.
- Market sentiment has favored BRKR amid broader sector rotation toward growth-oriented instrument providers, while WAT has shown more defensive price behavior.
- Relative performance differentials highlight trade-offs between growth momentum (BRKR) and stability with scale (WAT).
Introduction
Bruker Corporation (BRKR) and Waters Corporation (WAT) are established providers of analytical and life-sciences instrumentation used across research, diagnostics, and quality-control applications. Investors and traders focused on the healthcare technology and industrial instrumentation sectors often compare the two names to assess relative positioning within a cyclical yet innovation-driven market. This comparison examines recent price behavior, business fundamentals, and market dynamics to help market participants evaluate how each stock has responded to prevailing conditions over recent weeks and broader periods.
BRKR Overview and Recent Performance
Bruker Corporation develops and manufactures scientific instruments, including mass spectrometry, nuclear magnetic resonance, and X-ray systems, serving academic, pharmaceutical, and industrial customers. In recent market activity, BRKR shares have shown pronounced upward movement, with year-to-date returns exceeding 33 percent and one-year gains reaching approximately 50 percent or higher according to multiple market data sources. The stock reached a 52-week high near $65.30 amid sector interest in advanced analytical tools. Positive analyst commentary and upward price-target revisions have contributed to sentiment, while the company prepares to release second-quarter 2026 results on August 4. Broader market rotation toward growth names in the life-sciences tools space has supported trading volumes and price resilience in recent weeks.
WAT Overview and Recent Performance
Waters Corporation specializes in high-performance liquid chromatography, mass spectrometry, and thermal analysis instruments, with a strong presence in pharmaceutical and environmental testing markets. WAT shares have exhibited more measured price action, posting near-flat or modestly negative year-to-date returns around 0 to negative 2 percent, while one-year performance has remained positive in the low-to-mid 20 percent range. The stock has traded within a 52-week band of roughly $275 to $414, demonstrating relative stability compared with more volatile peers. As with BRKR, WAT is scheduled to report second-quarter 2026 earnings on August 4. Recent market data indicate defensive characteristics, with lower volatility and consistent institutional interest helping to limit downside during periods of sector rotation.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of the platform’s highest-performing artificial-intelligence trading bots from a pool of several hundred available strategies. Only those demonstrating the strongest alignment with prevailing market conditions, risk-adjusted returns, and relevant ticker coverage are featured in this section. Available bots span diverse trading styles, timeframes, and performance profiles, with curated examples showing returns up to +241 percent and win rates in the 70–80 percent range across selected strategies. Each robot employs distinct quantitative models and focuses on different market segments, allowing users to review statistics, backtested results, and live signals before deployment. The page provides a centralized resource for traders seeking data-driven automation tailored to current conditions.
Head-to-Head Comparison
BRKR and WAT share exposure to the analytical-instrumentation industry yet differ in scale, growth trajectory, and recent market reception. Bruker’s smaller market capitalization and emphasis on specialized high-end systems have translated into stronger recent momentum, while Waters’ larger installed base and recurring revenue streams from consumables support steadier cash flows. Growth drivers for BRKR include expanding adoption of advanced spectrometry solutions, whereas WAT benefits from entrenched positions in regulated pharmaceutical workflows. Risk factors differ as well: BRKR has experienced higher price volatility tied to product-cycle timing, while WAT faces potential pressure from slower organic growth in certain segments. Sector sentiment has recently tilted toward names with clearer near-term catalysts, creating a contrast in relative performance that reflects these structural differences.
Tickeron AI Verdict
Based on observable trend consistency, relative price momentum, and positioning ahead of shared earnings catalysts, Tickeron’s AI models currently assign a higher probabilistic preference to BRKR. The stock’s stronger recent performance and alignment with growth-oriented rotation within the sector contribute to this assessment, though outcomes remain subject to earnings results and broader market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRKR is a Buy and WAT is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 1 FA rating(s) are green whileWAT’s FA Score has 2 green FA rating(s).
- BRKR’s FA Score: 1 green, 4 red.
- WAT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 4 TA indicator(s) are bullish while WAT’s TA Score has 4 bullish TA indicator(s).
- BRKR’s TA Score: 4 bullish, 5 bearish.
- WAT’s TA Score: 4 bullish, 4 bearish.
Price Growth
BRKR (@Medical/Nursing Services) experienced а +12.99% price change this week, while WAT (@Medical Specialties) price change was +3.46% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +1.60%. For the same industry, the average monthly price growth was +2.00%, and the average quarterly price growth was -4.72%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.00%. For the same industry, the average monthly price growth was +7.63%, and the average quarterly price growth was +23.29%.
Reported Earning Dates
BRKR is expected to report earnings on Oct 29, 2026.
WAT is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Medical/Nursing Services (+1.60% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-1.00% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BRKR | WAT | BRKR / WAT | |
| Capitalization | 8.82B | 40.6B | 22% |
| EBITDA | 306M | 991M | 31% |
| Gain YTD | 23.260 | 8.867 | 262% |
| P/E Ratio | 74.88 | 104.69 | 72% |
| Revenue | 3.46B | 3.77B | 92% |
| Total Cash | N/A | 462M | - |
| Total Debt | 1.67B | 5.57B | 30% |
BRKR | WAT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 45 Fair valued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 84 | |
SMR RATING 1..100 | 92 | 85 | |
PRICE GROWTH RATING 1..100 | 38 | 9 | |
P/E GROWTH RATING 1..100 | 5 | 3 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BRKR's Valuation (45) in the Medical Specialties industry is somewhat better than the same rating for WAT (78). This means that BRKR’s stock grew somewhat faster than WAT’s over the last 12 months.
WAT's Profit vs Risk Rating (84) in the Medical Specialties industry is in the same range as BRKR (100). This means that WAT’s stock grew similarly to BRKR’s over the last 12 months.
WAT's SMR Rating (85) in the Medical Specialties industry is in the same range as BRKR (92). This means that WAT’s stock grew similarly to BRKR’s over the last 12 months.
WAT's Price Growth Rating (9) in the Medical Specialties industry is in the same range as BRKR (38). This means that WAT’s stock grew similarly to BRKR’s over the last 12 months.
WAT's P/E Growth Rating (3) in the Medical Specialties industry is in the same range as BRKR (5). This means that WAT’s stock grew similarly to BRKR’s over the last 12 months.
| BRKR | WAT | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 61% |
| Momentum ODDS (%) | 2 days ago 74% | 2 days ago 67% |
| MACD ODDS (%) | 2 days ago 56% | 2 days ago 64% |
| TrendWeek ODDS (%) | 2 days ago 70% | 2 days ago 63% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 61% |
| Advances ODDS (%) | 3 days ago 69% | 3 days ago 61% |
| Declines ODDS (%) | 19 days ago 73% | 12 days ago 64% |
| BollingerBands ODDS (%) | 2 days ago 70% | 2 days ago 62% |
| Aroon ODDS (%) | 2 days ago 67% | N/A |
Advertisement
BRKR and
Correlation & Price change
A.I.dvisor indicates that over the last year, BRKR has been closely correlated with A. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if BRKR jumps, then A could also see price increases.
| Ticker / NAME | Correlation To BRKR | 1D Price Change % | ||
|---|---|---|---|---|
| BRKR | 100% | -2.26% | ||
| A - BRKR | 78% Closely correlated | +0.71% | ||
| MTD - BRKR | 75% Closely correlated | -0.54% | ||
| WAT - BRKR | 68% Closely correlated | -0.63% | ||
| RVTY - BRKR | 68% Closely correlated | -0.32% | ||
| TMO - BRKR | 66% Loosely correlated | -1.18% | ||
More | ||||
WAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, WAT has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if WAT jumps, then A could also see price increases.
| Ticker / NAME | Correlation To WAT | 1D Price Change % | ||
|---|---|---|---|---|
| WAT | 100% | -0.63% | ||
| A - WAT | 68% Closely correlated | +0.71% | ||
| RVTY - WAT | 64% Loosely correlated | -0.32% | ||
| TMO - WAT | 60% Loosely correlated | -1.18% | ||
| BRKR - WAT | 58% Loosely correlated | -2.26% | ||
| CRL - WAT | 56% Loosely correlated | -1.09% | ||
More | ||||